- $36.9 BnWorld market, 2023
- $340.9 BnProjected, 2033
- 24.9%Growth a year (CAGR)
- –Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$15.5 Bn
22.9% a year · 42% of the world -
2
China
$3 Bn
26.4% a year · 8% of the world -
3
Canada
$3 Bn
24.9% a year · 8% of the world -
4
Japan
$2.3 Bn
25.4% a year · 6.2% of the world -
5
Germany
$1.4 Bn
23.1% a year · 3.7% of the world -
6
France
$1 Bn
23.9% a year · 2.8% of the world -
7
UK
$959 Mn
22.9% a year · 2.6% of the world -
8
Brazil
$923 Mn
25.9% a year · 2.5% of the world -
9
Italy
$886 Mn
24.4% a year · 2.4% of the world -
10
Ecuador
$738 Mn
25.5% a year · 2% of the world
Biosimilars by country and region
| Place | 2023 | 2033 (projected) | CAGR | World share | Active trials | Report |
|---|---|---|---|---|---|---|
| World | $36.9 Bn | $340.9 Bn | 24.9% | – | – | Report on Biosimilars in Global |
| North America | $18.5 Bn | $157.3 Bn | 23.9% | 50% | – | Report on Biosimilars in North America |
| APAC | $7.7 Bn | $79.2 Bn | 26.2% | 21% | – | Report on Biosimilars in APAC |
| Europe | $7 Bn | $58.5 Bn | 23.6% | 19% | – | Report on Biosimilars in Europe |
| Latin America | $1.7 Bn | $16.6 Bn | 25.9% | 4.5% | – | Report on Biosimilars in Latin America |
| Middle East | $1.5 Bn | $14.8 Bn | 25.9% | 4% | – | Report on Biosimilars in Middle East |
| Africa | $554 Mn | $5.8 Bn | 26.4% | 1.5% | – | Report on Biosimilars in Africa |
| US |
$15.5 Bn | $121.8 Bn | 22.9% | 42% | – | Report on Biosimilars in US |
| China |
$3 Bn | $30.9 Bn | 26.4% | 8% | – | Report on Biosimilars in China |
| Canada |
$3 Bn | $27.3 Bn | 24.9% | 8% | – | Report on Biosimilars in Canada |
| Japan |
$2.3 Bn | $22.1 Bn | 25.4% | 6.2% | – | Report on Biosimilars in Japan |
| Germany |
$1.4 Bn | $10.8 Bn | 23.1% | 3.7% | – | Report on Biosimilars in Germany |
| France |
$1 Bn | $8.7 Bn | 23.9% | 2.8% | – | Report on Biosimilars in France |
| UK |
$959 Mn | $7.5 Bn | 22.9% | 2.6% | – | Report on Biosimilars in UK |
| Brazil |
$923 Mn | $9.2 Bn | 25.9% | 2.5% | – | Report on Biosimilars in Brazil |
| Italy |
$886 Mn | $7.9 Bn | 24.4% | 2.4% | – | Report on Biosimilars in Italy |
| Ecuador |
$738 Mn | $7.2 Bn | 25.5% | 2% | – | Report on Biosimilars in Ecuador |
 Spain |
$712 Mn | $6.1 Bn | 23.9% | 1.9% | – | Report on Biosimilars in Spain |
 India |
$671 Mn | $7.9 Bn | 27.9% | 1.8% | – | Report on Biosimilars in India |
 Saudi Arabia |
$627 Mn | $6.5 Bn | 26.4% | 1.7% | – | Report on Biosimilars in Saudi Arabia |
 Mexico |
$554 Mn | $5.2 Bn | 25.2% | 1.5% | – | Report on Biosimilars in Mexico |
 Australia |
$443 Mn | $4.6 Bn | 26.4% | 1.2% | – | Report on Biosimilars in Australia |
 South Africa |
$240 Mn | $2.4 Bn | 26.1% | 0.6% | – | Report on Biosimilars in South Africa |
 UAE |
$185 Mn | $1.8 Bn | 25.9% | 0.5% | – | Report on Biosimilars in UAE |
 Egypt |
$103 Mn | $1.1 Bn | 26.4% | 0.3% | – | Report on Biosimilars in Egypt |
 Philippines |
$81 Mn | $781 Mn | 25.4% | 0.2% | – | Report on Biosimilars in Philippines |
 Malaysia |
$59 Mn | $557 Mn | 25.1% | 0.2% | – | Report on Biosimilars in Malaysia |
 Hong Kong |
$59 Mn | $592 Mn | 25.9% | 0.2% | – | Report on Biosimilars in Hong Kong |
 Singapore |
$44 Mn | $429 Mn | 25.5% | 0.1% | – | Report on Biosimilars in Singapore |
 Thailand |
$44 Mn | $420 Mn | 25.2% | 0.1% | – | Report on Biosimilars in Thailand |
 Kenya |
$26 Mn | $261 Mn | 26% | 0.1% | – | Report on Biosimilars in Kenya |
 New Zealand |
– | – | – | – | – | Report on Biosimilars in New Zealand |
 Russia |
– | – | – | – | – | Report on Biosimilars in Russia |
"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 3,452 papers since 2021
- Adapting the WHO Global Competency Framework for Regulators of Medicines: Implementation lessons from the South African Health Products Regulatory Authority. British journal of clinical pharmacology, 2026
- Effectiveness and Safety Outcomes After Switching from Reference Biologics to Biosimilars for Treatment of Non-Infectious Uveitis: A Systematic Review and Meta-Analysis. Clinical ophthalmology (Auckland, N.Z.), 2026
- Cost-effectiveness analysis of cetuximab for the treatment of head and neck cancers in India. Frontiers in pharmacology, 2026
- A Comparison of Two Strategies for Converting to Adalimumab Biosimilarsa. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026
- Infant-onset mevalonate kinase deficiency with a previously unreported MVK c.827 A > G (p.Glu276Gly) variant presenting as suspected incomplete kawasaki disease with marked hyperinflammation: clinical response to firsekibart and systematic evidence synthesis. Pediatric rheumatology online journal, 2026
Compare Biosimilars side by side
Key companies in Biosimilars
Novartis
Pfizer
Catalent
Amgen
Biogen
Patheon
Shanghai Henlius Biotech
Viatris
Celltrion
Recent Developments:
Quick answers
How big is the Biosimilars market?
The world Biosimilars market was worth about $36.9 Bn in 2023 and is projected to reach $340.9 Bn by 2033, growing 24.9% a year (CAGR).
Which country has the largest Biosimilars market?
The US is the largest of the 24 countries we cover, at $15.5 Bn in 2023. India grows fastest, at 27.9% a year.
How much research is published on Biosimilars?
PubMed lists about 3,452 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.